BTK
Los inhibidores de la tirosina quinasa de Bruton (BTK) son compuestos que específicamente se dirigen e inhiben la BTK, una enzima crucial involucrada en la señalización del receptor de células B y en la regulación de la angiogénesis. La BTK desempeña un papel significativo en la proliferación y supervivencia de las células cancerosas, particularmente en las malignidades hematológicas. Al inhibir la BTK, estos compuestos pueden interrumpir la angiogénesis y el crecimiento tumoral, lo que los convierte en valiosos en la terapia contra el cáncer. En CymitQuimica, ofrecemos una gama de inhibidores de BTK de alta calidad para apoyar su investigación en oncología, inmunología y angiogénesis.
Se han encontrado 146 productos de "BTK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Tirabrutinib hydrochloride
CAS:<p>Tirabrutinib hydrochloride is a potent, highly selective, irreversible oral BTK inhibitor.Cost-effective and quality-assured.</p>Fórmula:C25H23ClN6O3Pureza:99.04% - 99.27%Forma y color:SolidPeso molecular:490.94ARQ 531
CAS:<p>ARQ-531: potent oral BTK inhibitor, anti-cancer potential, IC50 of 0.85/0.39 nM for WT/C481S-BTK.</p>Fórmula:C25H23ClN4O4Pureza:98.68% - 99.63%Forma y color:SolidPeso molecular:478.93MT-802
CAS:<p>MT-802 is an effective BTK degrader based on PROTAC technology (DC50: 1 nM). MT-802 has the potential to treat C481S mutant chronic lymphocytic leukemia (CLL).</p>Fórmula:C41H41N9O8Pureza:95.93% - 97%Forma y color:SolidPeso molecular:787.82Btk inhibitor 2
CAS:<p>Btk inhibitor 2 (BGB-3111 analog) is a BTK inhibitor.</p>Fórmula:C24H25N5O3Pureza:99.94%Forma y color:SolidPeso molecular:431.49AS-1763
CAS:<p>AS-1763 is an orally available and selective BTK inhibitor with an IC50 of 0.85 nM.</p>Fórmula:C33H31FN6O3Pureza:≥95%Forma y color:SolidPeso molecular:578.64IBT6A
CAS:<p>IBT6A is an impurity of Ibrutinib. Ibrutinib is a Btk inhibitor (IC50: 0.5 nM). IBT6A can be used in the synthesis of IBT6A Ibrutinib dimer and IBT6A adduct.</p>Fórmula:C22H22N6OPureza:99.8% - 99.88%Forma y color:SolidPeso molecular:386.45Rilzabrutinib
CAS:<p>Rilzabrutinib (PRN1008) is a reversible covalent, selective and oral active inhibitor of Bruton’s Tyrosine Kinase (BTK)(IC50 of 1.3 nM).</p>Fórmula:C36H40FN9O3Pureza:98.28% - 99.76%Forma y color:SolidPeso molecular:665.76Orelabrutinib
CAS:<p>Orelabrutinib (ICP-022) is an orally active and irreversible inhibitor of Bruton's tyrosine kinase (BTK).</p>Fórmula:C26H25N3O3Pureza:97.77% - 99.54%Forma y color:SolidPeso molecular:427.49FDU73
<p>FDU73 is a potent and selective BTK PROTAC degrader with a DC50 of 2.9 nM in JeKo-1 cells. It inhibits tumor cell proliferation and exhibits antitumor activity.</p>Forma y color:Odour SolidBTK ligand-14
<p>BTKligand-14 is a PROTAC-targeting ligand for BTK, suitable for the synthesis of FDU73.</p>Forma y color:Odour SolidPROTAC BTK Degrader-5
<p>PROTAC BTK Degraders-5 (Compound 3e) is a selective Bruton's tyrosine kinase (BTK) degrader with a DC50 of 7.0 nM in JeKo-1 cells, demonstrating specificity by</p>Fórmula:C52H57ClFN9O6Pureza:98%Forma y color:SolidPeso molecular:958.52Tyrosinase-IN-16
CAS:<p>Tyrosinase-IN-16 inhibited tyrosinase.</p>Fórmula:C8H6BrN3SPureza:99.57%Forma y color:SolidPeso molecular:256.12DBt-10
<p>DBt-10 is a potent Bruton's tyrosine kinase (BTK) degrader [1].</p>Fórmula:C68H86ClFN16O6Pureza:98%Forma y color:SolidPeso molecular:1277.96PROTAC BTK Degrader-6
CAS:<p>PROTAC BTK Degrader-6 (Compound 15), with a DC50 of 3.18 nM, exhibits anti-inflammatory properties by inhibiting NF-κB activation and suppressing the expression</p>Fórmula:C45H47N11O6Pureza:98%Forma y color:SolidPeso molecular:837.92BTK-IN-40
CAS:<p>BTK-IN-40 (compound 375) is an inhibitor of BTK.</p>Fórmula:C20H25N7O2Forma y color:SolidPeso molecular:395.46FDA-Approved Kinase Inhibitor Library
<p>A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.</p>Forma y color:LiquidBTK-IN-5
CAS:<p>BTK-IN-5 is a covalent inhibitor of Bruton's tyrosine kinase (BTK) designed for the treatment of medical conditions including cardiovascular diseases,</p>Fórmula:C23H32N4O5Forma y color:SolidPeso molecular:444.532PROTAC BTK Degrader-2
CAS:<p>PROTAC BTK Degrader-2, a potent degrader of BTK through the PROTAC mechanism, effectively diminishes BTK protein levels [1].</p>Fórmula:C47H54F2N8O13Forma y color:SolidPeso molecular:976.97GBD-9
CAS:<p>GBD-9, a dual-mechanism degrader, effectively promotes the degradation of BTK and GSPT1 through recruitment of E3 ligase cereblon (CRBN).</p>Fórmula:C44H47N9O6Pureza:98%Forma y color:SolidPeso molecular:797.9Acalabrutinib enantiomer
CAS:<p>R-Acalabrutinib, a BTK inhibitor,enantiomer, is researched for cancer, autoimmune diseases, and inflammation.</p>Fórmula:C26H23N7O2Pureza:97.27%Forma y color:SolidPeso molecular:465.51CNX-500
CAS:<p>CNX-500: covalent Btk inhibitor linked to biotin, IC50 0.5 nM, low effect on EGFR and Src kinases.</p>Fórmula:C48H68N10O9SPureza:98%Forma y color:SolidPeso molecular:961.18evobrutinib
CAS:<p>Evobrutinib(M2951) , also known as M-2951 and MSC-2364447C, is a highly selective inhibitor of the Bruton's tyrosine kinase (BTK), which is important in the</p>Fórmula:C25H27N5O2Pureza:98.03% - 99.58%Forma y color:SolidPeso molecular:429.51BRK inhibitor P21d hydrochloride
CAS:<p>BRK inhibitor P21d HCl targets breast tumor kinase with 30 nM IC50, suppresses p-SAM68 at 52 nM, useful for in vivo breast cancer research.</p>Fórmula:C23H23ClFN7O2Forma y color:SolidPeso molecular:483.93PTD10
CAS:<p>PTD10, a highly potent PROTAC BTK degrader, exhibits a DC50 of 0.5 nM and a KD of 2.28 nM.</p>Fórmula:C49H51N11O8Pureza:98%Forma y color:SolidPeso molecular:922BTK inhibitor 17
CAS:<p>BTK inhibitor 17 is a potent irreversible BTK inhibitor (IC50 = 2.1 nM). BTK inhibitor 17 can be used in rheumatoid arthritis studies.</p>Fórmula:C25H24N6O3Pureza:99.57% - 99.88%Forma y color:SolidPeso molecular:456.5PCI-33380
CAS:<p>PCI-33380 is an irreversible inhibitor of Bruton's Tyrosine Kinase.</p>Fórmula:C46H52BF2N11O3Pureza:98%Forma y color:SolidPeso molecular:855.8Ibrutinib-biotin
CAS:<p>Ibrutinib-biotin probe links Ibrutinib to biotin, with IC50 0.755-1.02 nM for BTK (patent WO2014059368A1).</p>Fórmula:C56H80N12O9SPureza:98%Forma y color:SolidPeso molecular:1097.39TLT8
<p>TLT8 is a ByeTAC protein degrader that targets BTK. It induces BTK degradation by non-covalently binding to Rpn-13 and BTK. TLT8 is applicable in research on chronic lymphocytic leukemia.</p>Forma y color:Odour SolidDD 03-171
CAS:<p>Potent BTK Degrader, IC50=5.1nM, CRBN-dependent, suppresses MCL; degrades Ibrutinib-resistant BTK, no kinases binding, reduces tumors in models.</p>Fórmula:C55H62N10O8Forma y color:SolidPeso molecular:991.163BTK inhibitor 19
CAS:<p>BTK inhibitor 19 is a highly selective, covalent BTK inhibitor ( IC 50 = 2.7 nM).</p>Fórmula:C25H24F3N7O3Forma y color:SolidPeso molecular:527.508PROTAC BTK Degrader-12
CAS:<p>PROTAC BTK Degrader-12 (EXAMPLE 19) is a PROTAC-based BTK degrader, featuring a structure where the BTK ligand and linker are highlighted in pink and black, the linker in black, and the VHL ligand in blue.</p>Fórmula:C47H54N12O4Forma y color:SolidPeso molecular:851.01PROTAC BTK Degrader-10
CAS:<p>PROTAC BTK Degrader-10 (Example 1P) is a PROTAC compound that targets BTK for degradation. It is applicable in the research of chronic lymphocytic leukemia (CLL). [Pink: ligand for target protein; Black: linker; Blue: ligand for E3 ligase Cereblon].</p>Fórmula:C42H49N11O4Forma y color:SolidPeso molecular:771.91PROTAC BTK Degrader-13
<p>PROTAC BTK Degrader-13 (Compound 25) is a targeted BTK PROTAC degrader with a DC50 of 0.27 μM. It inhibits BTK activity with an IC50 of 0.44 μM and suppresses IL-2-induced T cell kinase (ITK) with an IC50 of 2.16 μM. This compound also inhibits the p38 MAPK signaling pathway, thereby blocking the activation of the BCR (B cell receptor) signaling pathway. [Pink: ligand for target protein BTK ligand 15; Black: linker; Blue: ligand for E3 ligase cereblon]</p>Fórmula:C33H30N6O7Forma y color:SolidPeso molecular:622.63PROTAC BTK Degrader-1
CAS:<p>Potent, selective oral PROTAC BTK Degrader-1; IC50: 34.51 nM (WT), 64.56 nM (BTK-481S); reduces BTK protein, inhibits tumors.</p>Fórmula:C43H43N9O4Forma y color:SolidPeso molecular:749.86PROTAC BTK Degrader-8
<p>PROTACBTK Degrader-8 (compound 3) is an efficient PROTAC BTK degrader with a linker that can couple with ADC antibodies to form PAC.</p>Fórmula:C80H94F2N14O20P2Peso molecular:1670.62121PROTAC BTK Degrader-9
<p>PROTACBTK Degrader-9 (compound 23) is a potent PROTACs degrader that specifically targets BTK. It effectively downregulates the RANKL-activated BTK-PLCγ2-Ca2+-NFATc1 signaling pathway. Consequently, PROTACBTK Degrader-9 inhibits osteoclastogenesis and reduces alveolar bone resorption in a mouse model of periodontitis.</p>Fórmula:C46H52FN13O5Peso molecular:885.41984Ibrutinib dimer
CAS:<p>Ibrutinib dimer is an impurity of Ibrutinib. IIbrutinib dimer is a Dimer of Ibrutinib. Ibrutinib is an irreversible Btk inhibitor (IC50: 0.5 nM).</p>Fórmula:C50H48N12O4Pureza:98%Forma y color:SolidPeso molecular:880.99SJF620 hydrochloride
CAS:<p>SJF620 hydrochloride is a PROTAC that utilizes a lenalidomide analog to recruit CRBN and ligands to target Btk, exhibiting a DC50 of 7.9 nM [1].</p>Fórmula:C41H45ClN8O7Pureza:98%Forma y color:SolidPeso molecular:797.3NRX-0492
CAS:<p>NRX-0492: orally active BTK degrader, induces ubiquitylation/proteasomal breakdown, potent with DC50 ≤0.2 nM, DC90 ≤0.5 nM, disrupts BCR signaling.</p>Fórmula:C43H51N11O6Forma y color:SolidPeso molecular:817.94BIIB091
CAS:<p>BIIB091 is a highly selective, reversible BTK inhibitor for treating autoimmune diseases.</p>Fórmula:C28H34N10O2Forma y color:SolidPeso molecular:542.648BCPyr
CAS:<p>BCPyr is a new candidate BTK degrader ( DC 50 = 800 nM).</p>Fórmula:C58H65F2N11O8Forma y color:SolidPeso molecular:1082.224GDC-0834
CAS:<p>GDC-0834 inhibits BTK with an in vitro IC50 of 5.9 and 6.4 nM in biochemical and cellular assays, respectively, and in vivo IC50 of 1.1 and 5.6 μM in mouse and</p>Fórmula:C33H36N6O3SForma y color:SolidPeso molecular:596.74Elsubrutinib
CAS:<p>Elsubrutinib (ABBV-105) is a highly active, potent, and selective orally-administered inhibitor of Bruton's tyrosine kinase (BTK). It irreversibly inhibits the catalytic domain of BTK with an IC50 value of 0.18 μM. Elsubrutinib holds potential for the advancement of research on inflammatory diseases.</p>Fórmula:C17H19N3O2Forma y color:SolidPeso molecular:297.358IBT6A hydrochloride
CAS:<p>IBT6A hydrochloride: Ibrutinib impurity, Btk inhibitor IC50: 0.5 nM, used in dimer/adduct synthesis.</p>Fórmula:C22H23ClN6OForma y color:SolidPeso molecular:422.91Anti-BTK Antibody (3G585)
<p>Anti-BTK Antibody (3G585) is an antibody targeting BTK. Anti-BTK Antibody (3G585) can be used in ELISA, IHC.</p>Forma y color:Odour LiquidN-piperidine Ibrutinib hydrochloride
CAS:<p>N-piperidine Ibrutinib hydrochloride is a BTK inhibitor that inhibits WT BTK and C481S BTK , which inhibits the growth and proliferation of cancer cells.</p>Fórmula:C22H23ClN6OPureza:98.83%Forma y color:SolidPeso molecular:422.91NX-5948
CAS:<p>NX-5948 (BTK-IN-24) is a PROTAC-type BTK degrader with anti-inflammatory and anticancer activities, inhibiting B cell activation.</p>Fórmula:C42H54N12O5Pureza:98.29%Forma y color:SolidPeso molecular:806.96Poseltinib
CAS:<p>Poseltinib is an oral, irreversible BTK inhibitor (IC50 1.95 nM) with higher selectivity over BMX, TEC, and TXK, blocking BCR, FcR, and TLR signaling.</p>Fórmula:C26H26N6O3Forma y color:SolidPeso molecular:470.52(S)-Sunvozertinib
CAS:<p>(S)-Sunvozertinib (DZD9008) is a rationally designed selective, irreversible EGFR/HER2 inhibitor.</p>Fórmula:C29H35ClFN7O3Pureza:99.64%Forma y color:SolidPeso molecular:584.08Tolebrutinib
CAS:<p>Tolebrutinib is an oral, selective BTK inhibitor, effective for MS research, with brain penetration and IC50s of 0.4/0.7 nM in cells.</p>Fórmula:C26H25N5O3Pureza:98.4% - 98.82%Forma y color:SolidPeso molecular:455.51(Z)-LFM-A13
CAS:(Z)-LFM-A13(IC50=2.5 μM), a specific Bruton's tyrosine kinase (BTK), is more than 100-fold specificity than other protein kinases, such as JAK1, JAK2, HCK, EGFR, and IRK.Fórmula:C11H8Br2N2O2Pureza:99.88%Forma y color:SolidPeso molecular:360Fenebrutinib
CAS:<p>Fenebrutinib (GDC-0853) is a selective and noncovalent Btk inhibitor (Ki: 0.91 nM).</p>Fórmula:C37H44N8O4Pureza:98.26% - 98.94%Forma y color:SolidPeso molecular:664.8Ibrutinib
CAS:<p>Ibrutinib (PCI-32765) is an irreversible inhibitor of BTK (IC50: 0.5 nM) that selectively blocks B cell activation.</p>Fórmula:C25H24N6O2Pureza:98% - 99.93%Forma y color:SolidPeso molecular:440.5PCI 29732
CAS:<p>PCI 29732 is a selective and irreversible Btk inhibitor with IC50 of 8.2 nM in a FRET based biochemical enzymology assay.</p>Fórmula:C22H21N5OPureza:99.81%Forma y color:SolidPeso molecular:371.43Remibrutinib
CAS:<p>Remibrutinib inhibits BTK activity with an IC50 value of 0.023 μM in blood.</p>Fórmula:C27H27F2N5O3Pureza:99.5% - 99.81%Forma y color:SolidPeso molecular:507.53BIIB068
CAS:<p>BIIB068 is an selective, reversible and orally active BTK inhibitor (IC50 = 1 nM, Kd = 0.3 nM). BIIB068 is 400 times more selective for BTK than other kinases.</p>Fórmula:C23H29N7O2Pureza:97.98%Forma y color:SolidPeso molecular:435.52Ibrutinib deacryloylpiperidine
CAS:<p>Ibrutinib deacryloylpiperidine (IBT4A) is a highly selective Bruton’s tyrosine kinase (BTK) irreversible inhibitor with an IC50 of 0.5 nM.</p>Fórmula:C17H13N5OPureza:99.47%Forma y color:SolidPeso molecular:303.32CHMFL-BMX-078
CAS:<p>CHMFL-BMX-078 is a highly potent and selective type II irreversible BMX kinase inhibitor with an IC50 of 11 nM.</p>Fórmula:C33H35N7O6Pureza:>99.99%Forma y color:SolidPeso molecular:625.67N-piperidine Ibrutinib
CAS:<p>N-piperidine Ibrutinib is a potent BTK inhibitor with IC50s of 51.0 for WT BTK and 30.7 nM for C481S BTK respectively.</p>Fórmula:C22H22N6OPureza:96.65%Forma y color:SolidPeso molecular:386.45zanubrutinib
CAS:<p>Zanubrutinib (BGB-3111) is an inhibitor of Bruton tyrosine kinase (BTK).</p>Fórmula:C27H29N5O3Pureza:98.42% - 99.76%Forma y color:SolidPeso molecular:471.55BMS-986142
CAS:<p>BMS-986142 is a potent and highly selective reversible BTK inhibitor (IC50: 0.5 nM).</p>Fórmula:C32H30F2N4O4Pureza:98.7% - 99.76%Forma y color:SolidPeso molecular:572.6Acalabrutinib
CAS:<p>Acalabrutinib (ACP-196), also known as ACP-196, is an orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity.</p>Fórmula:C26H23N7O2Pureza:98.94% - 99.64%Forma y color:SolidPeso molecular:465.51(Rac)-IBT6A
CAS:<p>(Rac)-IBT6A is a racemate of IBT6A. IBT6A is an impurity of Ibrutinib and can be used in the synthesis of IBT6A Ibrutinib dimer and IBT6A adduct.</p>Fórmula:C22H22N6OPureza:99.24%Forma y color:SolidPeso molecular:386.45TL-895
CAS:<p>TL-895 is a potent, selective ATP-competitive BTK inhibitor (IC50 = 1.5 nM, Ki = 11.9 nM).</p>Fórmula:C25H26FN5O2Pureza:99.96%Forma y color:SolidPeso molecular:447.5Spebrutinib
CAS:<p>Spebrutinib (LMK-435) is an orally bioavailable, selective inhibitor of Bruton's agammaglobulinemia tyrosine kinase (BTK), with potential antineoplastic</p>Fórmula:C22H22FN5O3Pureza:97.02% - >99.99%Forma y color:SolidPeso molecular:423.44ONO-4059 analog
CAS:<p>ONO-4059 analog (ONO-WG-307)ue is an analogue of ONO-4059, which is a highly potent and selective oral BTK inhibitor with IC50 of 23.9 nM. Phase 1.</p>Fórmula:C25H24N6O3Pureza:99.25%Forma y color:SolidPeso molecular:456.5RN486
CAS:<p>RN486 is an effective and specific BTK inhibitor (IC50: 4 nM).</p>Fórmula:C35H35FN6O3Pureza:99.38%Forma y color:SolidPeso molecular:606.69Branebrutinib
CAS:<p>Branebrutinib (BMS986195) is a potent, covalent inhibitor of Bruton's tyrosine kinase (BTK), >5,000-fold selective over all kinases outside of the Tec family.</p>Fórmula:C20H23FN4O2Pureza:95.86% - 99.31%Forma y color:SolidPeso molecular:370.42Larotinib mesylate hydrate
CAS:<p>Larotinib mesylate hydrate is a potent, broad-spectrum, and orally active tyrosine kinase inhibitor (TKI), primarily targeting EGFR with an IC50 value of 0.6 nM</p>Fórmula:C26H36ClFN4O11S2Forma y color:SolidPeso molecular:699.17CNX-774
CAS:<p>CNX-774 is a highly specific, irreversible, and orally active BTK inhibitor (IC50<1 nM).</p>Fórmula:C26H22FN7O3Pureza:97.35% - 99.11%Forma y color:SolidPeso molecular:499.5CGI-1746
CAS:<p>CGI1746 is a potent and highly selective small-molecule Btk inhibitor with IC50 of 1.9 nM.</p>Fórmula:C34H37N5O4Pureza:97.69% - 97.88%Forma y color:SolidPeso molecular:579.69Avitinib
CAS:<p>Avitinib (AC0010), also known as AC0010 or AC0010MA, is an orally available, irreversible, epidermal growth factor receptor (EGFR) mutant-selective inhibitor,</p>Fórmula:C26H26FN7O2Pureza:99.81% - >99.99%Forma y color:SolidPeso molecular:487.53BTK IN-1
CAS:<p>BTK IN-1 (SNS062 analog) (SNS062 analog) is an effective BTK inhibitor (IC50: <100 nM).</p>Fórmula:C19H21ClN6OPureza:97.38%Forma y color:SolidPeso molecular:384.86BTK Protein, Human, Recombinant (His)
<p>Non-receptor tyrosine kinase indispensable for B lymphocyte development, differentiation and signaling.</p>Pureza:90%Forma y color:Lyophilized PowderPeso molecular:78.3 kDa (predicted)Ibrutinib-d5
CAS:<p>Ibrutinib D5 is a deuterium-labeled Ibrutinib. Ibrutinib is an irreversible Btk inhibitor.</p>Fórmula:C25H24N6O2Pureza:98%Forma y color:SolidPeso molecular:445.53SJF620
CAS:<p>SJF620 is a potent degrader of PROTAC BTK(DC50 : 7.9 nM).</p>Fórmula:C41H44N8O7Pureza:98%Forma y color:SolidPeso molecular:760.84JAK3/BTK-IN-5
CAS:<p>JAK3/BTK-IN-5 is a potent dual inhibitor targeting JAK3 and BTK with synergistic effects, valuable for related autoimmune disease research.</p>Fórmula:C19H22ClN7O2Forma y color:SolidPeso molecular:415.88JS25
CAS:<p>JS25, a selective BTK inhibitor, inactivates it with a 5.8 nM IC50, halts cancer cell growth, induces death, and aids against lymphoma.</p>Fórmula:C29H24N4O4SForma y color:SolidPeso molecular:524.59BLK-IN-2
CAS:<p>BLK-IN-2为一种高效、选择性且不可逆的B-淋巴酪氨酸激酶(BLK)抑制剂，具有5.9 nM的IC50值。该化合物亦能抑制BTK，其IC50值为202.0 nM。BLK-IN-2在多种淋巴瘤细胞中展现出显著的抗增殖作用。</p>Fórmula:C39H41N9O3Forma y color:SolidPeso molecular:683.8GDC-0834 Racemate
CAS:<p>GDC-0834 Racemate is the racemate form of GDC-0834, which is an effective and selective BTK inhibitor</p>Fórmula:C33H36N6O3SForma y color:SolidPeso molecular:596.74EGFR-IN-40
CAS:<p>EGFR-IN-40 (compound 3z) is a potent inhibitor of BTK (IC50: 1.2 nM), EGFR (IC50: 5.3 nM) and ITK (IC50: 46.1 nM).</p>Fórmula:C23H20N6O3Forma y color:SolidPeso molecular:428.44BTK inhibitor 10
CAS:<p>BTK inhibitor 10, an oral drug from patent WO2018145525, may treat rheumatoid arthritis.</p>Fórmula:C25H23N5O3Pureza:98%Forma y color:SolidPeso molecular:441.48Ibrutinib-MPEA
CAS:<p>Ibrutinib-MPEA is ibrutinib derivative. Ibrutinib is a covalent and irreversible BTK inhibitor that has been used to treat hematological malignancies.</p>Fórmula:C32H39N9O2Forma y color:SolidPeso molecular:581.71JNJ-64264681
CAS:<p>JNJ-64264681 is a potent, orally active, selective, and irreversible covalent inhibitor of Bruton's tyrosine kinase (BTK).</p>Fórmula:C27H30N6O3SPureza:98%Forma y color:SolidPeso molecular:518.63(R)-Elsubrutinib
CAS:<p>(R)-Elsubrutinib ((R)-ABBV-105), a Btk inhibitor, is used in research on immune diseases and cancer.</p>Fórmula:C17H19N3O2Forma y color:SolidPeso molecular:297.35DPPY
CAS:<p>DPPY inhibits EGFR, BTK, JAK3 (IC50<10 nM), curbs B-cell lymphoma growth, and may be studied for IPF treatment.</p>Fórmula:C25H26ClN7O3Forma y color:SolidPeso molecular:507.97SB-633825
CAS:<p>SB-633825 can inhibit cancer cell growth and angiogenesis.</p>Fórmula:C28H25N3O3SPureza:98%Forma y color:SolidPeso molecular:483.58Spebrutinib besylate
CAS:<p>Spebrutinib besylate (AVL-292 benzenesulfonate; CC-292 besylate) is a Btk kinase activity inhibitor (IC50<0.5 nM, Kinact/Ki=7.69×104 M-1s-1s).</p>Fórmula:C28H28FN5O6SPureza:98%Forma y color:SolidPeso molecular:581.62ACP-5862
CAS:<p>ACP-5862, active metabolite of Acalabrutinib, is a BTK inhibitor with an IC50 of 5.0 nM.</p>Fórmula:C26H23N7O3Forma y color:SolidPeso molecular:481.51CHMFL-BTK-01
CAS:<p>CHMFL-BTK-01 is an irreversible inhibitor of BTK (IC50: 7 nM) and also potently inhibits BTK Y223 auto-phosphorylation.</p>Fórmula:C38H41N5O5Pureza:98%Forma y color:SolidPeso molecular:647.76JAK3/BTK-IN-6
CAS:<p>JAK3/BTK-IN-6: potent BTK (0.6 nM) & JAK3 (0.4 nM) inhibitor, stable in human liver, for blood/immune research.</p>Fórmula:C21H17BF3N5O3Forma y color:SolidPeso molecular:455.2BI-1622
CAS:<p>BI-1622, an oral HER2 inhibitor, IC50: 7 nM, >25x selectivity over EGFR, shows effective in vivo antitumor activity.</p>Fórmula:C26H24N10O2Forma y color:SolidPeso molecular:508.53BLK-IN-1
CAS:<p>BLK-IN-1 selectively blocks BLK and BTK with IC50s of 18.8 and 20.5 nM, used in cancer research.</p>Fórmula:C29H23F3N6O3Forma y color:SolidPeso molecular:560.53BTK-IN-23
CAS:<p>BTK-IN-23: BTK inhibitor, IC50=12.8 nM; also blocks BLX (35.6 nM), BMX (5.7 nM); better selectivity than Ibrutinib.</p>Fórmula:C27H28N6O2Forma y color:SolidPeso molecular:468.55PF-06465469
CAS:<p>PF-06465469 is a covalent ITK inhibitor(IC50: 2 nM).</p>Fórmula:C30H33N7O2Pureza:98%Forma y color:SolidPeso molecular:523.63VA5 TG2 inhibitor
CAS:<p>VA5 inhibits transamidase and GTP-binding by locking protein in an open state, disabling GTPase.</p>Fórmula:C31H34N4O8Pureza:98%Forma y color:SolidPeso molecular:590.62BTK-IN-22
CAS:<p>BTK-IN-22 is a selective BTK inhibitor with IC50 of 0.9 nM; also targets BLX, BMX (IC50s: 1.4, 1.2 nM); better selectivity than Ibrutinib.</p>Fórmula:C26H26N6O2Forma y color:SolidPeso molecular:454.52CGI560
CAS:<p>CGI560 is a potent BTK inhibitor with IC50 = 400 nM for BTK.</p>Fórmula:C29H27N5OForma y color:SolidPeso molecular:461.56HZ-A-005
CAS:<p>HZ-A-005 is a selective, potent, covalent inhibitor of Bruton's tyrosine kinase (BTK). HZ-A-005 significantly inhibits tumour growth in a xenograft mouse model.</p>Fórmula:C25H23ClN6O2Forma y color:SolidPeso molecular:474.94BLK degrader 1
CAS:<p>BLK degrader 1 is a BLK degrader with anticancer activity for cancer research.</p>Fórmula:C32H25F3N6O2Pureza:99.22% - 99.24%Forma y color:SolidPeso molecular:582.58GDC-0834 S-enantiomer
CAS:<p>GDC-0834, the S-enantiomer, is a potent and selective inhibitor of Bruton's tyrosine kinase (BTK).</p>Fórmula:C33H36N6O3SPureza:98%Forma y color:SolidPeso molecular:596.74CHMFL-EGFR-202
CAS:<p>CHMFL-EGFR-202 is a potent, irreversible inhibitor of EGFR mutant kinase (IC50s: 5.3 nM and 8.3 nM for drug-resistant mutant EGFR T790M and WT EGFR kinases).</p>Fórmula:C25H24ClN7O2Pureza:99.66%Forma y color:SolidPeso molecular:489.96(±)-Zanubrutinib
CAS:<p>(±)-Zanubrutinib ((±)-BGB-3111) is a potent and orally available Bruton's tyrosine kinase (Btk) inhibitor that demonstrates superior oral bioavailability,</p>Fórmula:C27H29N5O3Pureza:99.09%Forma y color:SolidPeso molecular:471.55NX-2127
CAS:<p>NX-2127 (ETX2514 Triethylamine) is an orally active BTK inhibitor that induces degradation of mutant BTKC481S in cells.NX-2127 has potent antiproliferative</p>Fórmula:C39H45N9O5Pureza:99.07%Forma y color:SolidPeso molecular:719.83(R)-Zanubrutinib
CAS:<p>(R)-Zanubrutinib ((R)-BGB-3111) is a selective inhibitor of Bruton tyrosine kinase (BTK).</p>Fórmula:C27H29N5O3Pureza:99.55%Forma y color:SolidPeso molecular:471.55Tilfrinib
CAS:<p>Tilfrinib is an effective and selective inhibitor of breast tumor kinase(Brk, IC50 = 3.15 nM) which displays anti-proliferative and anti-tumor activities.</p>Fórmula:C17H13N3OPureza:99.54%Forma y color:SolidPeso molecular:275.3(Rac)-PF-06250112
CAS:<p>(Rac)-PF-0625011 is a racemic mix, orally active, selective BTK inhibitor, also targeting BMX and TEC kinases.</p>Fórmula:C22H20F2N6O2Pureza:98%Forma y color:SolidPeso molecular:438.43BTK-IN-19
CAS:<p>BTK-IN-19 is a reversible BTK inhibitor with an IC 50 of <0.001 μM .</p>Fórmula:C21H22Cl2N6OForma y color:SolidPeso molecular:445.35BTK inhibitor 20
CAS:<p>BTK inhibitor 20 is a potent BTK inhibitor with an IC 50 of 8 nM .</p>Fórmula:C37H42N8O4Forma y color:SolidPeso molecular:662.78BTK-IN-18
CAS:<p>BTK-IN-18 is a potent, reversible inhibitor of Bruton's tyrosine kinase (BTK) with an inhibitory concentration (IC50) of 0.002 µM.</p>Fórmula:C20H22Cl2N6OForma y color:SolidPeso molecular:433.33BTK-IN-17
<p>BTK-IN-17: selective, oral BTK inhibitor, IC50=13.7 nM, reduces p-BTK Y223/p-PLCγ2 Y1217, anti-inflammatory.</p>Fórmula:C26H23N7O2Forma y color:SolidPeso molecular:465.51BTK-IN-11
CAS:<p>BTK-IN-11: potent BTK inhibitor; may research autoimmune, inflammatory diseases, cancer. (Patent WO2022063101A1, Z2)</p>Fórmula:C26H22ClN5O3Forma y color:SolidPeso molecular:487.94PF-303
CAS:<p>PF-303, a reversible covalent BTK inhibitor, shows potential for cancer and autoimmune therapy.</p>Fórmula:C22H21ClN6O2Forma y color:SolidPeso molecular:436.89BTK inhibitor 13
CAS:<p>BTK inhibitor 13 (compound 8) is an effective and selective BTK inhibitor(IC50: 1.2 nM).</p>Fórmula:C29H26FN5O3Pureza:98%Forma y color:SolidPeso molecular:511.55Pirtobrutinib
CAS:<p>Pirtobrutinib: a selective, non-covalent BTK inhibitor effective against BTK C481 mutations, causing tumor regression in lymphoma models.</p>Fórmula:C22H21F4N5O3Pureza:99.76% - 99.94%Forma y color:SolidPeso molecular:479.43Cinsebrutinib
CAS:<p>Cinsebrutinib, a Bruton's tyrosine kinase inhibitor, holds potential for research in cancer treatment.</p>Fórmula:C22H26FN3O2Pureza:98%Forma y color:SolidPeso molecular:383.46Edralbrutinib
CAS:<p>Edralbrutinib (TG-1701) is a potent BTK inhibitor with anticancer activity and is used in the treatment of tumors, immune system disorders, and blood and</p>Fórmula:C26H21F2N5O3Pureza:99.41%Forma y color:SolidPeso molecular:489.47BMX-IN-1
CAS:<p>BMX-IN-1 (BMX kinase inhibitor) is a selective inhibitor of bone marrow tyrosine kinase on chromosome X (BMX, IC50 = 8 nM) and the related Bruton’s tyrosine</p>Fórmula:C29H24N4O4SPureza:98.38%Forma y color:SolidPeso molecular:524.59PF-06250112
CAS:<p>PF-06250112 is an effective and highly selective BTK inhibitor (IC50: 0.5 nM.</p>Fórmula:C22H20F2N6O2Pureza:98%Forma y color:SolidPeso molecular:438.43TAK-020
CAS:<p>TAK-020 is a potent covalent inhibitor of Btk with potential antitumor activity for the study of rheumatoid arthritis and immune-related diseases.</p>Fórmula:C18H17N5O3Pureza:98.79%Forma y color:SolidPeso molecular:351.36BTK inhibitor 1
CAS:<p>BTK inhibitor 1 (Compound 27) is a BTK inhibitor (IC50: 0.11 nM) with an inhibitory effect on B-cell activation in hWB with an IC50 of 2 nM.</p>Fórmula:C24H23FN8O2Pureza:98.24% - 98.91%Forma y color:SolidPeso molecular:474.49BMS-935177
CAS:<p>BMS-935177 is a reversible BTK inhibitor with IC50 value of 3 nM.</p>Fórmula:C31H26N4O3Pureza:99.89%Forma y color:SolidPeso molecular:502.56BTK inhibitor 18
<p>BTK inhibitor 18 is a selective, potent, covalent, orally active Btk inhibitor (IC50: 142 nM) that exhibits anti-inflammatory effects.</p>Fórmula:C29H25N5O4S2Forma y color:SolidPeso molecular:571.67HDHD4-IN-1
CAS:<p>HDHD4-IN-1 (compound 3) is an inhibitor of N-acetylneuraminate-9-phosphate phosphatase (HDHD4) with an IC50 value of 11 μM. It is utilized in the research of neurological disorders.</p>Fórmula:C12H22NO11PForma y color:SolidPeso molecular:387.28BMS-986143
CAS:<p>BMS-986143: oral BTK inhibitor, IC50=0.26 nM, potential for autoimmune research, also targets TEC, BLK, BMX, TXK, YES1, ITK.</p>Fórmula:C31H24Cl2N4O4Forma y color:SolidPeso molecular:587.45JAK3/BTK-IN-4
CAS:<p>JAK3/BTK-IN-4, a dual inhibitor for JAK3/BTK, shows synergy in autoimmune disease treatment. (Patent WO2021147953A1, compound 003)</p>Fórmula:C21H25ClN8OForma y color:SolidPeso molecular:440.93GNE-431
CAS:<p>GNE-431: potent, selective noncovalent Btk inhibitor, IC50=3.2 nM; effective against C481R, T474I, T474M mutants, may counter ibrutinib resistance.</p>Fórmula:C30H32N10O2Forma y color:SolidPeso molecular:564.64BIIB129
CAS:<p>BIIB129 is a selective and brain-penetrant BTK covalent inhibitor used to study B-cell proliferation-related diseases.</p>Fórmula:C19H22N6O2Pureza:98.56%Forma y color:SolidPeso molecular:366.42RET-IN-14
CAS:<p>RET-IN-14 inhibits RET (IC50: <0.51-9.3 nM) & BTK (C481S) (IC50: 9.2-15 nM), promising for tumor research.</p>Fórmula:C24H23FN8O4Forma y color:SolidPeso molecular:506.49BTK-IN-15
<p>BTK-IN-15: Oral BTK inhibitor, IC50 0.7 nM, induces cancer cell apoptosis, selective with anti-tumor effects.</p>Fórmula:C28H24FN5O2Forma y color:SolidPeso molecular:481.52WS-11
CAS:<p>WS-11 is a non-covalent reversible inhibitor of BTK, with IC50 values of 3.9 nM for the wild-type and 2.2 nM for the C481S mutant BTK. In addition to strong hydrogen bonding, WS-11 also forms robust π-π interactions with PHE540, and p-π interactions with LYS430 within the active pocket.</p>Fórmula:C26H22FN9O2Forma y color:SolidPeso molecular:511.51BTK-IN-16
CAS:<p>BTK-IN-16 is a potential inhibitor of wild-type BTK and C481S mutants.BTK-IN-16 can be used to study various autoimmune diseases and cancers caused by BTK.</p>Fórmula:C15H14N4O2Pureza:99.04%Forma y color:SoildPeso molecular:282.3G-744
CAS:<p>G-744 is a selective and orally active inhibitor of Btk (IC50: 2 nM).</p>Fórmula:C29H29N5O3SPureza:98%Forma y color:SolidPeso molecular:527.64JAK3/BTK-IN-3
CAS:<p>JAK3/BTK-IN-3: strong dual JAK3/BTK suppressor, promising for autoimmune disease research.</p>Fórmula:C22H28N8OForma y color:SolidPeso molecular:420.51BTK-IN-10
CAS:<p>BTK-IN-10 is a potent inhibitor of BTK, acting on wild-type BTK (IC50<5 nM) or mutant BTK (C481S) (IC50<5 nM).</p>Fórmula:C25H24F2N4O2Forma y color:SolidPeso molecular:450.48BTK-IN-34
CAS:BTK-IN-34 (compound 9h) functions as a selective BTK inhibitor, exhibiting antiproliferative effects in RAMOS cells by specifically targeting pBTK (Tyr223) while sparing upstream proteins such as Lyn and Syk in the BCR signaling pathway [1].Fórmula:C22H29N3O4SPeso molecular:431.55BTK-IN-38
CAS:<p>BTK-IN-38 (Example 125) is an efficacious inhibitor of BTK. It effectively suppresses the proliferation of DOHH2 and BT474 cells, with IC50 values of 114 nM and 340 nM, respectively.</p>Fórmula:C27H26F2N4O2Forma y color:SolidPeso molecular:476.52JAK3/BTK-IN-7
CAS:<p>JAK3/BTK-IN-7 (XL-12), characterized as a JAK3/BTK inhibitor, exhibits IC 50 values of 2 nM and 14 nM for JAK3 and BTK respectively. This compound demonstrates anti-inflammatory properties and is applicable in research related to rheumatoid arthritis [1].</p>Fórmula:C29H30N8O4Forma y color:SolidPeso molecular:554.6Brefeldin A 4-O-nicotinate
CAS:<p>Brefeldin A 4-O-nicotinate (CHNQD-01228) is a dual inhibitor of Arf1 and BMX proteins with an IC50 value of 0.22 μM for T24 cell proliferation. It also suppresses T24 cell migration and colony formation in a dose-dependent manner, induces G1 phase arrest, and triggers apoptosis. By targeting BMX proteins, it inhibits the AKT/p-AKT and STAT3/p-STAT3 signaling pathways, while also inhibiting Arf1 proteins to eliminate bladder cancer stem cells and activate antitumor immunity, thus exhibiting anticancer activity. Brefeldin A 4-O-nicotinate is applicable in research related to bladder cancer.</p>Fórmula:C22H27NO5Forma y color:SolidPeso molecular:385.453BTK-IN-8
<p>BTK-IN-8: potent, selective covalent BTK inhibitor; IC50=0.22 nM, Kd=0.91 nM; effective in blood CD69 cells (IC50=0.029 μM).</p>Fórmula:C26H36N6O3Forma y color:SolidPeso molecular:480.6BTK-IN-6
<p>BTK-IN-6, a potent BTK inhibitor, may treat immune, cardiac, cancer, viral, inflammatory, metabolic, and neurological disorders.</p>Fórmula:C23H22FN5O3Forma y color:SolidPeso molecular:435.45Ibrutinib Racemate
CAS:<p>Ibrutinib is a selective, irreversible Btk inhibitor (IC50: 0.5 nM). Ibrutinib Racemate is the racemate of Ibrutinib.</p>Fórmula:C25H24N6O2Pureza:98%Forma y color:SolidPeso molecular:440.5Dihydrodiol-Ibrutinib
CAS:<p>PCI 45227 is an active metabolite of the Bruton's tyrosine kinase inhibitor ibrutinib .1PCI 45227 is formed from ibrutinib by the cytochrome P450 (CYP) isoform CYP3A.<br>1.Veeraraghavan, S., Viswanadha, S., Thappali, S., et al.Simultaneous quantification of lenalidomide, ibrutinib and its active metabolite PCI-45227 in rat plasma by LC-MS/MS: Application to a pharmacokinetic studyJ. Pharm. Biomed. Anal.107151-158(2015)</p>Fórmula:C25H26N6O4Forma y color:SolidPeso molecular:474.521BTK-IN-25
CAS:<p>BTK-IN-25 (compound 71) is a potent BTK inhibitor, demonstrating an IC50 of 0.77 nM against BTK(C481S) and achieving an IC50 of 1 nM in DOHH2 cells [1].</p>Fórmula:C28H27F2N3O5Pureza:98%Forma y color:SolidPeso molecular:523.53JDB175
CAS:<p>JDB175, a selective BTK inhibitor with oral bioavailability, demonstrates excellent penetration through the blood-brain barrier.</p>Fórmula:C26H21F3N4O2Pureza:98%Forma y color:SolidPeso molecular:478.47BTK-IN-27
CAS:<p>BTK-IN-27 (example 8), a potent BTK inhibitor with an IC50 of 0.2 nM, demonstrates anti-proliferative effects in TMD8 cells with an IC50 of less than 5 nM.</p>Fórmula:C31H35N7O2Pureza:98%Forma y color:SolidPeso molecular:537.66
